Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›
Research›
Government Agencies›
University of Iowa Roy J. and Lucille A. Carver College of Medicine›
Analysis
AddedFeb 15, 2024
UpdatedJun 8, 2026
University of Iowa Roy J. and Lucille A. Carver College of Medicine

University of Iowa Roy J. and Lucille A. Carver College of Medicine

Operating

Carver College of Medicine is Iowa's LCME-accredited public medical school, offering MD, PA, and DPT programs.

Founded
1870
Location
Iowa City, IA, US
Loading
Overview
Analysis
Compare
Employees
Website

Contents

  1. 01Products & Services
  2. 02Market Outlook
  3. 03Competitive Strengths
  1. 01Products & Services
  2. 02Market Outlook
  3. 03Competitive Strengths

Product Overview

The Carver College of Medicine offers a four-year Doctor of Medicine program accredited by the Liaison Committee on Medical Education, serving as Iowa’s only LCME-accredited allopathic medical school. Its curriculum integrates basic sciences with early clinical experiences across University of Iowa Health Care facilities, the Iowa City Veterans Affairs Medical Center, and regional medical education sites.

In addition to the MD program, the college offers highly ranked graduate health sciences programs, including a physician assistant program tied for No. 1 nationally and a physical therapy program ranked No. 2 by U.S. News & World Report for 2026–2027. The college also supports graduate medical education through residency and fellowship training in a broad range of specialties.

Market Outlook

Demand for Carver College of Medicine graduates remains strong, with Match Day outcomes showing placement across dozens of specialties and states; the Class of 2026 matched into 29 specialties across 32 states, and more than half entered primary care fields. The college’s emphasis on rural and underserved populations aligns with state and national health workforce priorities, as reflected in U.S. News rankings for graduates practicing in rural areas and health professional shortage areas.

The college’s research enterprise continues to expand, supported by major centers such as the Francois M. Abboud Cardiovascular Research Center and the Fraternal Order of Eagles Diabetes Research Center. Sustained investment in interprofessional education, biomedical research, and statewide clinical partnerships positions the institution to address evolving health care needs in Iowa and beyond.

Competitive Advantages

Carver College of Medicine holds the distinction of being Iowa’s only LCME-accredited allopathic medical school, giving it a unique role in training physicians for the state and region. Its physician assistant and physical therapy programs are consistently ranked among the top five nationally, with the PA program ranked No. 1 and the DPT program ranked No. 2 in the 2026–2027 U.S. News & World Report Best Graduate Schools rankings.

The college is also a leading academic medical center for research, supported by more than 80 core research facilities and over 280 laboratories, with UI Health Care research teams securing more than $250 million in external funding in the past year. Longstanding institutional strengths include pioneering contributions to diabetes, cardiovascular disease, neuroscience, and orthopedic care.